Gene engineering biological therapy for juvenile arthritis

Михельс, Х.; Michels, H.; Nikishina, Irina; Федоров, Е. С.; Салугина, С. О.

doi:10.14412/1995-4484-2011-873

Cited by 5 publications

(1 citation statement)

References 135 publications

(135 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В мире имеется поло-жительный опыт применения адалимумаба в лечении ревматических заболеваний [9][10][11], в т. ч. юношеского полиартрита, включая результаты рандомизированных клинических исследований [12][13][14].…”

Section: Discussionunclassified

The Experience of Switching to the Second TNF Inhibitor in a Patient With Severe Juvenile Polyarthritis and Resistance to the First TNF-Blocker

Алексеева¹,

Дворяковская²,

Денисова³

et al. 2017

Vopr. sovr. pediatr.

View full text Add to dashboard Cite

Section: Discussionunclassified

The Experience of Switching to the Second TNF Inhibitor in a Patient With Severe Juvenile Polyarthritis and Resistance to the First TNF-Blocker

Алексеева¹,

Дворяковская²,

Денисова³

et al. 2017

Vopr. sovr. pediatr.

View full text Add to dashboard Cite

Markers of genomic instability in patients with juvenile rheumatoid arthritis

Макарова

Ильина

2020

Ross. vestn. perinatol. pediatr.

View full text Add to dashboard Cite

Research purpose. To determine the state of the genome instability in patients with juvenile rheumatoid arthritis and to assess its dependence on biological (age and sex) and clinical (form and variant of the flow of juvenile rheumatoid arthritis, its activity, duration, functional class and serotype of the patient) parameters.Material and methods: 95 children were surveyed. Among them, 68 (39 girls and 29 boys) – with various forms of juvenile rheumatoid arthritis, 12 – without treatment (at the stage of verification of the diagnosis). The control group consisted of 15 conditionally healthy children aged 3 to 16 years. To assess the genome instability, the method of determination of micronuclei in peripheral blood binuclear lymphocytes under the conditions of a cytochalasin block (in vitro) was used.Results: All examined children in the active form of the disease showed a significant increase in the level of binuclear lymphocytes with micronuclei in lymphocytes compared with a group of conditionally healthy children. The maximum values of this indicator were observed in the age group from 5 to 10 years and in children with a disease duration of up to 1 year. As the activity of the process increases, the level of binuclear lymphocytes with micronuclei rises. After treatment, a significant decrease in the indicator content was detected in patients with the II degree of disease activity in both cases of juvenile rheumatoid arthritis.Conclusion. Statistically significant increase in the level of binuclear lymphocytes with micronuclei in peripheral blood lymphocytes may indicate the formation of genome instability in children as a pathogenetic part in juvenile rheumatoid arthritis.

show abstract

Experience of switching biological therapy in a patient with juvenile idiopathic arthritis and uveitis. Case report

Галстян

Verbitsky²,

Meleshkina³

et al. 2022

Pediatr. Con. Med.

View full text Add to dashboard Cite

Uveitis associated with juvenile arthritis can be complicated by cataracts, retinal edema, and glaucoma, which carries a potential risk of disability in the child's organ of vision. Approximately 2540% of patients demonstrate insufficient effectiveness of the ongoing standard antirheumatic therapy, which requires the inclusion of genetically engineered biological therapy. According to the protocols, the drug of choice for juvenile arthritis associated with uveitis is adalimumab, which has shown high efficacy in many studies. However, some patients stop responding to therapy over time, which raises the question of switching to another genetically engineered biological drug (GЕBD). Our article presents a case of severe course with an early onset of juvenile idiopathic arthritis associated with uveitis. Due to the insufficient effectiveness of basic monotherapy with methorexate, as well as topical glucocorticoids, adilimumab was added to therapy a year after the onset of the disease. Over the next 5 years, the child was on this therapy with exacerbations of uveitis about 12 episodes per year. Subsequently, uveitis began to continuously recur, which raised the question of the development of probable resistance to adalimumab and the change of GEBD. The girl was switched to golimumab, which is a human monoclonal antibody that can bind to tumor necrosis factor-. This drug has been used for the treatment of juvenile idiopathic arthritis since 2017 for children weighing 40 kg and above, and after the completion of the multicenter GO-KIDS study, it is registered for children from 2 years of age. According to a number of studies, golimumab has shown its effectiveness in relation to the activity of uveitis in patients with arthritis, including those in childhood. In general, the issues of switching GEBD in cases of ineffective therapy with first-line drugs are a very urgent problem in pediatric rheumatology. In our case, switching to the GIBP golimumab resulted in a positive effect on the activity of rheumatoid uveitis and induction of remission of the articular syndrome.

show abstract

Gene engineering biological therapy for juvenile arthritis

Cited by 5 publications

References 135 publications

The Experience of Switching to the Second TNF Inhibitor in a Patient With Severe Juvenile Polyarthritis and Resistance to the First TNF-Blocker

The Experience of Switching to the Second TNF Inhibitor in a Patient With Severe Juvenile Polyarthritis and Resistance to the First TNF-Blocker

Markers of genomic instability in patients with juvenile rheumatoid arthritis

Experience of switching biological therapy in a patient with juvenile idiopathic arthritis and uveitis. Case report

Contact Info

Product

Resources

About